title: Basolateral amygdala opioids contribute to increased high-fat intake following intra-accumbens opioid administration, but not following 24-h food deprivation.
abstract: Previous research has demonstrated that administration of μ-opioid receptor agonists into the nucleus accumbens increases high-fat diet consumption in sated rats and has shown a role of basolateral amygdala (BLA) activity in mediating this response. The present experiments were conducted to examine the role of BLA opioid transmission in mediating high-fat feeding driven by either intra-accumbens opioid activation or 24-h home cage food deprivation. Injection of the μ-opioid agonist, d-Ala2-NMe-Phe4-Glyol5-enkephalin (DAMGO) into the nucleus accumbens (0.25μg/0.5μl/side) increased consumption of a high-fat diet, and this effect was attenuated by pre-treatment with the opioid antagonist, naltrexone (5μg/0.25μl/side) administered into the BLA. In contrast, intra-BLA naltrexone administration had no influence on the increase in high-fat intake following 24-h food deprivation. These findings suggest that BLA opioid transmission is an important mediator of palatability-driven feeding as modeled by intra-accumbens opioid activation, while BLA opioid transmission has no significant influence on the increase in high-fat feeding driven by short-term negative-energy balance.
authors.affiliation: Department of Psychological Sciences, University of Missouri, Columbia, MO, Christopher S. Bond Life Sciences Center, United States. kepfg4@mail.mizzou.edu
authors.forename: Kyle E
authors.initials: KE
authors.lastname: Parker
authors.forename: Jordan G
authors.initials: JG
authors.lastname: McCall
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Will
mesh_terms: D000679:Amygdala / Q000187:drug effects*; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D004032:Diet; D004041:Dietary Fats; D004435:Eating / Q000187:drug effects*; D004734:Energy Metabolism / Q000187:drug effects; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000008:administration & dosage / Q000494:pharmacology*; D005508:Food Deprivation / Q000502:physiology*; D008297:Male; D008845:Microinjections; D009043:Motor Activity / Q000187:drug effects; D009271:Naltrexone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009714:Nucleus Accumbens; D051381:Rats; D017207:Rats, Sprague-Dawley; D009435:Synaptic Transmission / Q000187:drug effects
chemical_list: D000701:Analgesics, Opioid; D004041:Dietary Fats; D009292:Narcotic Antagonists; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D009271:Naltrexone
references.citation: Ann N Y Acad Sci. 2003 Apr;985:185-205
references.pmid: 12724159
references.citation: J Neurosci. 2007 Apr 11;27(15):3937-45
references.pmid: 17428967
references.citation: Brain Res. 1980 Sep 22;197(2):291-317
references.pmid: 7407557
references.citation: Brain Res. 2004 Dec 10;1029(1):135-9
references.pmid: 15533326
references.citation: Physiol Behav. 2007 Feb 28;90(2-3):362-7
references.pmid: 17078980
references.citation: Brain Res Bull. 1982 Jul-Dec;9(1-6):321-53
references.pmid: 6816390
references.citation: J Neurosci. 2009 Feb 25;29(8):2486-95
references.pmid: 19244523
references.citation: J Comp Neurol. 1998 Oct 5;399(4):440-68
references.pmid: 9741477
references.citation: Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12512-7
references.pmid: 19597155
references.citation: Physiol Behav. 2004 Apr;81(2):179-209
references.pmid: 15159167
references.citation: Behav Brain Res. 2010 Jul 29;211(1):58-63
references.pmid: 20214927
references.citation: Nat Neurosci. 1998 Jun;1(2):155-9
references.pmid: 10195132
references.citation: Neuron. 2002 Oct 10;36(2):199-211
references.pmid: 12383777
references.citation: Brain Res Brain Res Rev. 2001 Dec;38(1-2):247-89
references.pmid: 11750934
references.citation: Behav Brain Res. 2007 Jul 19;181(1):110-7
references.pmid: 17507102
references.citation: Brain Res. 1992 Jul 17;586(1):104-10
references.pmid: 1324775
references.citation: Behav Neurosci. 2009 Aug;123(4):781-93
references.pmid: 19634936
references.citation: Psychopharmacology (Berl). 2002 Feb;159(4):415-23
references.pmid: 11823894
references.citation: Brain Res. 1984 Aug;319(3):229-59
references.pmid: 6478256
references.citation: J Neurosci. 2003 Apr 1;23(7):2882-8
references.pmid: 12684475
references.citation: Neuroscience. 1982 Mar;7(3):615-30
references.pmid: 7070669
references.citation: Physiol Rev. 2003 Jul;83(3):803-34
references.pmid: 12843409
references.citation: Appetite. 2004 Dec;43(3):315-7
references.pmid: 15527935
references.citation: Science. 1993 May 14;260(5110):989-91
references.pmid: 8493536
references.citation: J Neurosci Methods. 1980 Dec;3(2):129-49
references.pmid: 6110810
references.citation: Neuroreport. 2004 Aug 26;15(12):1857-60
references.pmid: 15305124
references.citation: J Neurosci. 2005 Dec 14;25(50):11777-86
references.pmid: 16354936
references.citation: Nature. 2008 Jul 31;454(7204):600-6
references.pmid: 18615015
references.citation: Behav Neurosci. 2005 Oct;119(5):1195-206
references.pmid: 16300426
references.citation: Trends Pharmacol Sci. 1992 May;13(5):177-84
references.pmid: 1604710
references.citation: Neurosci Biobehav Rev. 1996;20(1):1-25
references.pmid: 8622814
references.citation: Physiol Behav. 2005 Dec 15;86(5):773-95
references.pmid: 16289609
references.citation: Brain Res. 1994 Jun 20;648(2):342-6
references.pmid: 7922551
references.citation: Physiol Behav. 2009 Jul 14;97(5):537-50
references.pmid: 19336238